{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:34:31Z","timestamp":1777905271883,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/00051\/2020"],"award-info":[{"award-number":["UIDP\/00051\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/00051\/2020"],"award-info":[{"award-number":["UIDB\/00051\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jacadv.2026.102589","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:23:38Z","timestamp":1770218618000},"page":"102589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Design, Rationale, and Methods of the INITIATE-HFrEF Trial"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cristina","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Saraiva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00eas","family":"Pereira-Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f3nio","family":"Ang\u00e9lico-Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Grij\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Pereira","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Gavina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4509-0260","authenticated-orcid":false,"given":"M\u00e1rio","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2306-8393","authenticated-orcid":false,"given":"Ricardo","family":"Fontes-Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Pimenta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adelino","family":"Leite-Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Vasques-N\u00f3voa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2026.102589_bib1","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus Enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102589_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102589_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102589_bib4","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.102589_bib5","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102589_bib6","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/ejhf.2149","article-title":"Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction","volume":"23","author":"Packer","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2026.102589_bib7","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCULATIONAHA.120.052926","article-title":"How should we sequence the treatments for heart failure and a reduced ejection fraction?: a redefinition of evidence-based medicine","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102589_bib8","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s10741-023-10325-2","article-title":"Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy","volume":"28","author":"Malgie","year":"2023","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacadv.2026.102589_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-Neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102589_bib10","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor Empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jacadv.2026.102589_bib11","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.102589_bib12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/eurheartj\/ehaa968","article-title":"Influence of Neprilysin inhibition on the efficacy and safety of Empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-reduced trial","volume":"42","author":"Packer","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.102589_bib13","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1093\/eurheartj\/ehaa183","article-title":"Effects of Dapagliflozin in DAPA-HF according to background heart failure therapy","volume":"41","author":"Docherty","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.102589_bib14","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1111\/dom.16429","article-title":"Trends in antidiabetic drug use in Portugal: 8 years real-world data from a nationwide retrospective observational study (2017-2024) (TREND-8 study)","author":"Neves","year":"2025","journal-title":"Diabetes obes Metab"},{"key":"10.1016\/j.jacadv.2026.102589_bib15","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial","author":"Packer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102589_bib16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamacardio.2020.7585","article-title":"Time to clinical benefit of Dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction","volume":"6","author":"Berg","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2026.102589_bib17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jchf.2020.04.008","article-title":"Effect of Dapagliflozin in patients with HFrEF treated with Sacubitril\/Valsartan: the DAPA-HF trial","volume":"8","author":"Solomon","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacadv.2026.102589_bib18","article-title":"Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacadv.2026.102589_bib19","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of Dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102589_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006623","article-title":"Practical considerations for the use of sodium-glucose Co-Transporter 2 inhibitors in heart failure","volume":"13","author":"Honigberg","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacadv.2026.102589_bib21","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1093\/eurheartj\/ehaf244","article-title":"Newly diagnosed heart failure with reduced ejection fraction: timing, sequencing, and titration of guideline-recommended medical therapy","volume":"46","author":"Malgie","year":"2025","journal-title":"Eur Heart J"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26000050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26000050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:42:46Z","timestamp":1777639366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26000050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2772963X26000050"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102589","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, Rationale, and Methods of the INITIATE-HFrEF Trial","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.12.070","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102589"}}